Carbapenem-resistant organisms: Difference between revisions
From IDWiki
(Created page with "== Background == * Mechanisms include decreased expression of porins, increased expression of efflux pumps, and carbapenemases == Management == === Novel Antibiotics ==...") |
No edit summary |
||
| Line 1: | Line 1: | ||
== |
==Background== |
||
* |
*Mechanisms include decreased expression of porins, increased expression of efflux pumps, and [[carbapenemases]] |
||
== |
==Management== |
||
=== Novel Antibiotics === |
|||
{| class="wikitable" |
{| class="wikitable" |
||
!Antibiotic |
!Antibiotic |
||
| Line 103: | Line 101: | ||
| style="color:darkgreen;text-align:center" | + |
| style="color:darkgreen;text-align:center" | + |
||
|} |
|} |
||
| ⚫ | |||
| ⚫ | |||
Revision as of 12:15, 21 September 2020
Background
- Mechanisms include decreased expression of porins, increased expression of efflux pumps, and carbapenemases
Management
| Antibiotic | KPC | NDM | OXA-48 | CRPsA | CRAcB | Stenotrophomonas |
|---|---|---|---|---|---|---|
| aztreonam-avibactam | + | + | + | ± | – | + |
| cefiderocol | + | + | + | + | + | + |
| ceftazidime-avibactam | + | – | + | ± | – | – |
| ceftolozane-tazobactam | – | – | – | ± | – | ± |
| eravacycline | + | + | + | – | + | + |
| fosfomycin | ± | ± | ± | ± | – | – |
| imipenem-relebactam | + | – | ± | + | – | – |
| meropenem-vaborbactam | + | – | – | – | – | – |
| plazomicin | + | ± | + | ± | – | – |
| colistin | ± | ± | ± | ± | ± | ± |
| tigecycline | + | + | + | – | + | + |
References
- ^ Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli, Jesús Rodríguez-Baño. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025.
